Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR ...
Tag: durvalumumab
1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
